Literature DB >> 34233370

Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity.

Marco Arrese1,2, Juan P Arab1,2, Francisco Barrera1,2, Benedikt Kaufmann3, Luca Valenti4, Ariel E Feldstein3.   

Abstract

The acronym nonalcoholic fatty-liver disease (NAFLD) groups a heterogeneous patient population. Although in many patients the primary driver is metabolic dysfunction, a complex and dynamic interaction of different factors (i.e., sex, presence of one or more genetic variants, coexistence of different comorbidities, diverse microbiota composition, and various degrees of alcohol consumption among others) takes place to determine disease subphenotypes with distinct natural history and prognosis and, eventually, different response to therapy. This review aims to address this topic through the analysis of existing data on the differential contribution of known factors to the pathogenesis and clinical expression of NAFLD, thus determining the different clinical subphenotypes observed in practice. To improve our understanding of NAFLD heterogeneity and the dominant drivers of disease in patient subgroups would predictably impact on the development of more precision-targeted therapies for NAFLD. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Entities:  

Year:  2021        PMID: 34233370     DOI: 10.1055/s-0041-1730927

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  10 in total

1.  Effects of Synbiotics, Probiotics, and Prebiotics on Liver Enzymes of Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis.

Authors:  Sukrit Kanchanasurakit; Chayanis Kositamongkol; Kamonnat Lanoi; Monnaree Nunta; Thaksaporn Saetuan; Nathorn Chaiyakunapruk; Surasak Saokaew; Pochamana Phisalprapa
Journal:  Front Nutr       Date:  2022-05-20

Review 2.  Histological assessment based on liver biopsy: the value and challenges in NASH drug development.

Authors:  Xiao-Fei Tong; Qian-Yi Wang; Xin-Yan Zhao; Ya-Meng Sun; Xiao-Ning Wu; Li-Ling Yang; Zheng-Zhao Lu; Xiao-Juan Ou; Ji-Dong Jia; Hong You
Journal:  Acta Pharmacol Sin       Date:  2022-02-14       Impact factor: 7.169

3.  Human Mesenchymal Stromal Cells Resolve Lipid Load in High Fat Diet-Induced Non-Alcoholic Steatohepatitis in Mice by Mitochondria Donation.

Authors:  Sandra Nickel; Madlen Christ; Sandra Schmidt; Joanna Kosacka; Hagen Kühne; Martin Roderfeld; Thomas Longerich; Lysann Tietze; Ina Bosse; Mei-Ju Hsu; Peggy Stock; Elke Roeb; Bruno Christ
Journal:  Cells       Date:  2022-06-02       Impact factor: 7.666

4.  Population-specific cut-off points of fatty liver index: a study based on the National Health and Nutrition Examination Survey data.

Authors:  Juan Wu; Shen Tian; Hao Li; Zhou Xu; Shu Li; Yu-Ling Chen; Xin-Yu Liang; Jun Xiao; Jing-Yu Song; Rui-Ling She; Chen-Yu Ma; Jun-Han Feng; Zhao-Xing Li; Zhi-Yu Jiang; Zi-Wei Zhang; Kai-Nan Wu; Ling-Quan Kong
Journal:  BMC Gastroenterol       Date:  2022-05-27       Impact factor: 2.847

5.  Adiposity, metabolomic biomarkers, and risk of nonalcoholic fatty liver disease: a case-cohort study.

Authors:  Yuanjie Pang; Christiana Kartsonaki; Jun Lv; Iona Y Millwood; Zammy Fairhurst-Hunter; Iain Turnbull; Fiona Bragg; Michael R Hill; Canqing Yu; Yu Guo; Yiping Chen; Ling Yang; Robert Clarke; Robin G Walters; Ming Wu; Junshi Chen; Liming Li; Zhengming Chen; Michael V Holmes
Journal:  Am J Clin Nutr       Date:  2022-03-04       Impact factor: 8.472

Review 6.  Nonalcoholic Fatty Liver Disease and Endocrine Axes-A Scoping Review.

Authors:  Madalena Von-Hafe; Marta Borges-Canha; Catarina Vale; Ana Rita Leite; João Sérgio Neves; Davide Carvalho; Adelino Leite-Moreira
Journal:  Metabolites       Date:  2022-03-29

Review 7.  Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?

Authors:  Ângelo Z Mattos; Jose D Debes; Arndt Vogel; Marco Arrese; Xavier Revelo; Tales Henrique S Pase; Muriel Manica; Angelo A Mattos
Journal:  World J Gastroenterol       Date:  2022-07-28       Impact factor: 5.374

8.  Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction.

Authors:  Amedeo Lonardo; Ashwani K Singal; Natalia Osna; Kusum K Kharbanda
Journal:  Metab Target Organ Damage       Date:  2022-08-22

Review 9.  Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models.

Authors:  María Pelechá; Estela Villanueva-Bádenas; Enrique Timor-López; María Teresa Donato; Laia Tolosa
Journal:  Antioxidants (Basel)       Date:  2021-12-30

10.  Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD.

Authors:  Javier Ampuero; Rocío Gallego-Durán; Douglas Maya-Miles; Rocío Montero; Sheila Gato; Ángela Rojas; Antonio Gil; Rocío Muñoz; Manuel Romero-Gómez
Journal:  J Gastroenterol       Date:  2022-03-24       Impact factor: 6.772

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.